Table 3.
Risk for GELs by 25(OH)D level
| N | Mean | Median (IQR) | |
|---|---|---|---|
| 25(OH)D levels | |||
| All | 15721 | 49.53 (22.97) | 45.34 (33.43–62.04) |
| Baseline | 457 | 45.87 (17.93) | 43.70 (31.55–56.46) |
| Month 6 | 359 | 48.83 (20.14) | 46.65 (34.50–60.64) |
| Month 12 | 349 | 43.38 (20.26) | 38.25 (29.17–55.08) |
| Month 24 | 386 | 60.30 (28.71) | 54.04 (39.02–76.20) |
| GEL count2 | |||
| All | 1493 | 0.89 (2.48) | 0.00 (0.00–1.00) |
| Baseline | 453 | 1.48 (3.38) | 0.00 (0.00–1.00) |
| Month 6 | 323 | 0.73 (2.17) | 0.00 (0.00–0.00) |
| Month 12 | 346 | 0.66 (1.88) | 0.00 (0.00–1.00) |
| Month 24 | 371 | 0.51 (1.68) | 0.00 (0.00–0.00) |
| 50 nmol/L increase in 25(OH)D | ≥50 nmol/L vs. <50 nmol/L | ||
|---|---|---|---|
| Unadjusted | Adjusted3 | Adjusted3 | |
| Relative risk of GEL by 25(OH)D level, RR [95% CI], P value | |||
| All | 0.45 [0.32–0.65], P < 0.0001 | 0.43 [0.28–0.66], P = 0.0001 | 0.61 [0.44–0.83], P = 0.002 |
| Baseline | 0.39 [0.30–0.49], P < 0.0001 | 0.38 [0.30–0.49], P < 0.0001 | – |
| Month 6 | 0.66 [0.47–0.93], P = 0.02 | 0.29 [0.17–0.50], P < 0.0001 | – |
| Month 12 | 0.65 [0.45–0.92], P = 0.02 | 0.99 [0.51–1.92], P = 0.99 | – |
| Month 24 | 0.70 [0.53–0.93], P = 0.01 | 1.03 [0.57–1.87], P = 0.91 | – |
GEL, gadolinium-enhancing lesion; 25(OH)D, 25-hydroxyvitamin D; IQR, interquartile range; RR, risk ratios.
1
Note that some 25(OH)D measurements were taken from samples from visits other than baseline, Months 6, 12, or 24. These were excluded from further analysis.
2
Note that only T1 scans are stated for which a 25(OH)D measurement was available.
3
Models were adjusted for age at time of measurement, gender, treatment, and the interaction of treatment and 25(OH)D level.